510(k) vs De Novo vs PMA: Medical Device Pathway Guide

A practical device-pathway decision guide comparing 510(k), De Novo, and PMA. It starts with intended use, risk, classification, and predicate availability rather than submission preference.

Reviewed by: BioBoston CRO Editorial Team

Five-step diagram for 510(k) vs De Novo vs PMA: Medical Device Pathway Guide: Define intended use, Assess risk, Check predicate, Select pathway, and Confirm evidence.

A 510(k) vs De Novo vs PMA comparison begins with intended use, device risk, classification, and appropriate predicate availability. Use the decision matrix to identify which regulatory assumptions need evidence or FDA feedback before selecting a route.

Practical principle: 510k vs de novo vs pma decisions begin with device classification, intended use, risk, and predicate availability. The three pathways answer different regulatory questions and require different evidence strategies.

Quick answer: when does each pathway fit?

Pathway Core fit Primary FDA question
510(k) A legally marketed predicate supports substantial equivalence Is the new device substantially equivalent to the predicate?
De Novo Novel low-to-moderate-risk device without an appropriate predicate Can general and special controls provide reasonable assurance of safety and effectiveness?
PMA Class III / high-risk device subject to PMA Does valid scientific evidence provide reasonable assurance of safety and effectiveness?

1. Define intended use before searching for a pathway

Write the intended use, indications, users, patient population, clinical setting, output, and consequence of error. Device names and technology labels are poor pathway anchors if the actual clinical use is unclear.

For sponsors that need hands-on support applying this framework, BioBoston CRO Regulatory Pathway can support the underlying regulatory and cross-functional work.

2. Search for an appropriate predicate — not merely a similar product

  • Same or sufficiently aligned intended use.
  • Technological characteristics that support substantial equivalence or can be addressed with performance evidence.
  • No difference that raises an unresolved different question of safety or effectiveness.
  • Legally marketed status and relevant product code/classification.

3. Use risk and controls to test De Novo fit

When no suitable predicate exists, ask whether the device can be classified into Class I or II because general controls alone, or general plus special controls, can provide reasonable assurance of safety and effectiveness. Novelty alone does not make a device De Novo-appropriate.

4. Recognize PMA-level evidence early

For Class III devices subject to PMA, the evidence program must independently support safety and effectiveness. Clinical, manufacturing, software, design, and labeling requirements should be integrated into the pathway plan early because late pathway changes are expensive.

5. Use Q-Submission feedback strategically

  • Predicate and substantial-equivalence strategy.
  • Proposed De Novo classification and special controls.
  • Clinical or performance-study design.
  • Software, cybersecurity, usability, or novel-technology testing as applicable.
  • PMA evidence and pivotal-study questions.

Pathway decision tree

  1. Is the device subject to PMA / Class III? If yes, plan PMA unless another classification route applies.
  2. If not, is there an appropriate legally marketed predicate supporting substantial equivalence? If yes, assess 510(k).
  3. If no predicate exists, can risks be controlled as Class I or II? If yes, assess De Novo.
  4. If uncertainty remains, frame the decision and evidence questions for FDA feedback before committing to the program.

Need help choosing the route?

BioBoston CRO Regulatory Pathway support can help assess classification, predicate strategy, evidence gaps, and FDA interaction options.

Related Resources

START A CONVERSATION

Tell Us What Support You Need

Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.


Please do not submit confidential, patient-identifiable, or proprietary information through this form.